Company Overview - Federated Hermes manages $845.7 billion in assets, including $211.3 billion in long-term managed assets: $89.0 billion in equity, $98.7 billion in fixed income, $20.7 billion in alternative/private markets, and $2.9 billion in multi-asset [12] - The company's total revenue for Q2 2025 was $424.8 million [14] - Federated Hermes has $634.4 billion in liquidity assets [10, 16] Asset Class Performance - Equity assets increased by $8.1 billion, a 10% rise from $80.9 billion as of March 31, 2025 [21] - Fixed-income assets decreased by $0.8 billion, a 1% decline from $99.5 billion as of March 31, 2025 [21] Revenue Diversification - In Q2 2025, money market funds contributed an average of 35% to revenue less distribution expense, with a high of 61% and a low of 13% [23] - Equity contributed an average of 43% to revenue less distribution expense, with a high of 56% and a low of 27% [23] - Fixed income contributed an average of 18% to revenue less distribution expense, with a high of 25% and a low of 11% [23] - Alternative/Private Markets and Multi-asset contributed an average of 9% to revenue less distribution expense, with a high of 19% and a low of 6% [23] Distribution Channels - U S Financial Intermediaries account for 67% of assets under management [26] - U S Institutional accounts for 26% of assets under management [26] - International accounts for 7% of assets under management [26] Capital Allocation - Since its IPO in 1998, Federated Hermes has allocated cash towards dividends (45%), share repurchases (35%), and acquisitions (20%) [77] - Total share repurchase, acquisition, and dividend payments since the IPO amount to $6.6 billion [78]

Financial Performance - Q2 2025 reported sales grew by 6% to $966 million[7, 14], with core sales growth of 3%[7, 14] - Q2 2025 reported earnings per share (EPS) increased by 25% to $167[7, 16] - Q2 2025 adjusted EPS grew by 18% to $166[7, 19] - Q2 2025 adjusted EBITDA increased by 13% to $218 million[21] - Year-to-date 2025 reported sales increased by 2% to $1853 million[33], with core sales growth of 2%[33] - Year-to-date 2025 reported EPS increased by 10% to $283[35] - Year-to-date 2025 adjusted EBITDA increased by 8% to $402 million[41] Segment Performance - Aptar Pharma's Q2 2025 sales increased by 7% to $443 million[24], with a 130 basis point improvement in adjusted EBITDA margin to 354%[24] - Aptar Beauty's Q2 2025 sales increased by 4% to $335 million[27], with a 20 basis point improvement in adjusted EBITDA margin to 141%[27] - Aptar Closures' Q2 2025 sales increased by 8% to $189 million[30], with a 130 basis point improvement in adjusted EBITDA margin to 169%[30] Outlook - The company expects Q3 2025 adjusted EPS to be between $153 and $161[44]

Financial Performance - Net revenues for 2Q25 were US$708 million, a 13% increase compared to 1Q25 (US$627 million) but a 4% decrease compared to 2Q24 (US$736 million)[14] - Adjusted EBITDA for 2Q25 was US$161 million, a 28% increase compared to 1Q25 (US$125 million) but a 22% decrease compared to 2Q24 (US$206 million)[14] - The company's net leverage ratio was 23x in 2Q25, compared to 21x in 1Q25 and 27x in 2Q24[14] - Free cash flow for 2Q25 was US$17 million, compared to US$(226) million in 1Q25 and US$149 million in 2Q24[14] Operational Highlights - Zinc production (mining) reached 74kt in 2Q25, up 9% from 1Q25 (67kt) but down 12% from 2Q24 (83kt)[14] - Total zinc sales (smelting) were 145kt in 2Q25, up 12% from 1Q25 (130kt) but down 2% from 2Q24 (148kt)[14] - Mining segment cash cost net of by-products was US$(011)/lb in 2Q25[19] - Smelting segment cash cost net of by-products was US$123/lb in 2Q25, a 5% increase QoQ and a 3% increase YoY[26] Strategic Initiatives and Outlook - The Cerro Pasco Integration Project is progressing, with Phase I execution advancing and technical studies for Phase II underway, aiming for a 15+ year LoM extension[34, 84] - Exploration efforts continue to reinforce geological potential, with promising intercepts at Cerro Lindo, Aripuanã, Vazante, and Cerro Pasco Complex[41, 42, 43, 44, 45] - The company expects higher Adjusted EBITDA in 2H25, driven by operational improvements and cost optimization initiatives[31]

Q2 2025 Performance - Revenue reached $3.5 billion, exceeding guidance expectations by 4% and showing a 20% increase compared to the previous year[5,6] - Adjusted EBITDA increased by 1% year-over-year, meeting guidance expectations[5] - Adjusted Diluted EPS was $1.49, surpassing the midpoint of guidance by $0.08 due to higher operating earnings and lower depreciation[5] - Cash flow from operations was $6 million[6] Backlog - Total backlog reached $16.5 billion, reflecting a sequential increase of $0.6 billion (4%) and a year-over-year growth of $3.1 billion (23%)[5] - Clean Energy and Infrastructure backlog increased by $506 million sequentially and approximately $1.3 billion year-over-year, reaching $4.9 billion[15] Segment Results (Q2 2025 Revenue) - Communications: $837 million[9] - Clean Energy and Infrastructure: $1.131 billion[9] - Power Delivery: $591 million[9] - Pipeline Infrastructure: $275 million[9] Financial Position - The company anticipates 2025 full year cash flow from operations will approximate $700 to $750 million[32] - The company expects 2025 leverage to remain below 2x[32] - Liquidity is at $2.0 billion[22] 2025 Guidance - Q3 Revenue Guidance: $3.9 billion[24] - Full Year Revenue Guidance: $13.9 billion - $14.0 billion[24] - Full Year Adjusted EBITDA Guidance: $1.13 billion - $1.16 billion[24] - Full Year Adjusted Diluted EPS Guidance: $6.23 - $6.44[24]

Financial Performance - Eversource Energy reported Q2 2025 EPS of $0.96, slightly better than the prior year[22] - The company reaffirms its 2025 EPS guidance of $4.67 - $4.82 and a long-term EPS growth rate of 5% - 7% through 2029[23] - The company's FFO to Debt ratio as of March 31, 2025, was 13.7%, exceeding the Moody's downgrade threshold of 9% and S&P's threshold of 12%[50] Capital Investments and Regulatory Updates - Eversource plans a capital investment of $24.2 billion through 2029, with 60% of distribution capital investment in Massachusetts[18] - The company anticipates incremental investments of $1.5 billion - $2 billion during this forecast period[47] - A permanent rate increase of $100 million was received in New Hampshire, effective August 1, 2025, as part of the PSNH rate case[39] - Massachusetts will see an EGMA Rate Base Reset with a November 2024 rate increase of $77 million and a November 2025 rate increase of $62 million[45] Strategic Priorities - Eversource is focused on being a 100% regulated utility, investing in line with state policies while maintaining customer reliability and affordability[18] - The company aims to strengthen its balance sheet and enhance its FFO to Debt ratio[18] - Eversource is leading the energy transition in New England with approximately $2 billion in T&D energy investments through 2029[18] Balance Sheet and Credit Metrics - Eversource has an At-The-Market (ATM) program for $1.2 billion of equity, issuing 3.4 million shares through June 2025 with net proceeds of $218 million[51, 60]

North America's Leading Copper Developer Permitted, In Construction, Scalable & Unmatched Corporate Presentation August 2025 TSX: FOM | US OTC: FMCXF | FORANMINING.COM TSX: FOM | US OTC: FMCXF | FORANMINING.COM Forward Looking Statements This presentation contains certain forward-looking information and forward-looking statements, as defined under applicable securities laws (collectively referred to herein as "forward-looking statements"). These statements relate to future events or to the future performanc ...

Financial Performance - Net sales increased by 1.0%[22] - Organic sales increased by 1.8%, including a 0.6% negative impact from lower private label pet sales[22] - Base Business EPS increased by 1%[22] Guidance - Net sales growth is still expected to be up low single digits, now including a flat to low-single-digit negative impact from foreign exchange[29] - Organic sales growth is now expected to be at the low end of 2% to 4%, including the impact over the course of 2025 of the planned exit from private label pet sales[32] - GAAP EPS is still expected to be up low single digits[29] - Base Business EPS is still expected to be up low single digits[32] Productivity Program - A new three-year productivity program is projected to result in cumulative pre-tax charges totaling between $200 and $300 million[26] Raw Material Costs - The company's current expectation for incremental tariff impact is approximately $75 million[36] Market Share - Global toothpaste market share was up 20 basis points on a volume basis year to date[22] Company Overview - Colgate-Palmolive is a $20.1B global consumer products company[7]

Financial Performance & Market Position - Cinemark reported second quarter total revenue of $941 million, a 28% increase year-over-year[35] - The company generated the highest quarterly Adjusted EBITDA and Adjusted EBITDA margin post-pandemic with $232 million and 24.7%, respectively[35] - Cinemark's domestic box office recovery surpassed the North American industry by over 1,000 basis points[35] - The company maintained core structural market share growth vs FY19 in excess of 100 bps in the U S and Latin America[35] - For the first half of 2025, Cinemark reported ~$1 5 billion of total revenue, an increase of 13% year-over-year[37] - Adjusted EBITDA for 1H25 was $269 million, representing an increase of 26% year-over-year, with an Adjusted EBITDA margin expansion of 190 bps to 18 1%[37] Assets & Customer Loyalty - Cinemark has consistently allocated $80-$100 million for global maintenance capex to maintain a high-quality circuit[15] - Approximately 70% of the U S footprint features reclined luxury seats[15] - Movie Club members increased to 1 45 million, growing 12% year-over-year and over 50% vs 2019, representing nearly 30% of domestic 2Q25 box office[35] Capital Allocation & Debt Management - The company is committed to repaying the $460 million principal amount of convertible notes maturing August 15, 2025, using cash on hand[48] - Cinemark repurchased $200 million of stock in March 2025 to proactively mitigate potential dilution from warrants, reducing share count by 7 93 million[48]

Financial Performance - Net sales decreased by 99% from $4383 million to $3948 million in Q2 2025[37] - Comparable sales decreased by 105%[37] - Adjusted earnings per share decreased by 243% from $037 to $028[37] - Adjusted free cash flow was an outflow of $24 million year-to-date[60] Segment Performance - ACCO Brands Americas sales decreased by 150% from $2923 million to $2485 million[42] - ACCO Brands International sales increased slightly by 02% from $1460 million to $1463 million[42] - ACCO Brands Americas adjusted operating income decreased by 316% from $632 million to $432 million[42] - ACCO Brands International adjusted operating income increased by 60% from $117 million to $124 million[42] Cost Reduction and Debt - The company is executing a multi-year cost reduction program targeting at least $100 million in savings[32] - Over $40 million in savings have been realized since the program's inception[35] - Net debt decreased by $19 million year-over-year[16] Outlook - Q3 2025 net sales are projected to be between $387 million and $400 million, a decrease of 50% to 80%[63] - Full year 2025 net sales are projected to be between $1525 billion and $1550 billion, a decrease of 70% to 85%[67]

Financial Performance - Regeneron reported total revenues of $3.68 billion for Q2 2025[8] - Non-GAAP EPS for Q2 2025 was $12.89[8] - Dupixent global net sales reached $4.3 billion in Q2 2025, representing a 21% year-over-year increase[9] - EYLEA HD and EYLEA together held approximately 61% of the U S branded anti-VEGF category share in Q2 2025[22] - Libtayo global net sales for Q2 2025 were $377 million, a 25% year-over-year increase[30] Dupixent Expansion - Dupixent is approved for eight indications globally and has reached approximately 12 million patients worldwide[9] - The U S FDA approved Dupixent for chronic spontaneous urticaria (CSU) in April 2025 and bullous pemphigoid (BP) in June 2025[9, 19] - Dupixent was approved by the FDA in late September 2024 for COPD[11] Pipeline Developments - Lynozyfic received approval in the U S and Europe for relapsed/refractory multiple myeloma and was added to NCCN treatment guidelines[8] - The company initiated the first Phase 3 study for Factor XI (REGN7508) in VTE prevention after total knee replacement surgery[8] - Regeneron in-licensed olatorepatide/HS-20094 (dual GLP-1/GIP receptor agonist) to evaluate as a monotherapy and study combinations to address muscle loss and other comorbidities of obesity[8] Reimbursement and Development Balance - Reimbursement of Sanofi's antibody development balance is expected to average approximately $800 million per year in 2025 and 2026[15] - As of June 30, 2025, the antibody development balance stood at approximately $1.2 billion[17]